|
US5002876A
(en)
|
1986-09-22 |
1991-03-26 |
Phillips Petroleum Company |
Yeast production of human tumor necrosis factor
|
|
US5004688A
(en)
|
1988-04-15 |
1991-04-02 |
Phillips Petroleum Company |
Purification of hepatitis proteins
|
|
US5007790A
(en)
|
1989-04-11 |
1991-04-16 |
Depomed Systems, Inc. |
Sustained-release oral drug dosage form
|
|
US5169645A
(en)
|
1989-10-31 |
1992-12-08 |
Duquesne University Of The Holy Ghost |
Directly compressible granules having improved flow properties
|
|
US5582837A
(en)
|
1992-03-25 |
1996-12-10 |
Depomed, Inc. |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
ATE173159T1
(de)
|
1992-03-25 |
1998-11-15 |
Depomed Systems Inc |
Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
|
|
WO1997047285A1
(en)
|
1996-06-10 |
1997-12-18 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
ES2248908T7
(es)
|
1997-06-06 |
2014-11-24 |
Depomed, Inc. |
Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
|
|
NZ518739A
(en)
|
1999-11-02 |
2004-12-24 |
Depomed Inc |
Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
|
|
PT1251832E
(pt)
|
2000-02-04 |
2007-01-31 |
Depomed Inc |
Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
|
|
US6488962B1
(en)
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
|
US20020077283A1
(en)
|
2000-09-08 |
2002-06-20 |
Sessa William C. |
Caveolin peptides and their use as therapeutics
|
|
US6451808B1
(en)
|
2000-10-17 |
2002-09-17 |
Depomed, Inc. |
Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
|
|
US20030031711A1
(en)
|
2001-05-29 |
2003-02-13 |
Fara John W. |
Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
|
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
JP2005508358A
(ja)
|
2001-10-25 |
2005-03-31 |
デポメド・インコーポレイテッド |
胃滞留型ロサルタン投与量を用いる治療方法
|
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
US20050181474A1
(en)
|
2002-01-30 |
2005-08-18 |
Frank J. Giordano |
Transport peptides and uses therefor
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
US7473531B1
(en)
*
|
2003-08-08 |
2009-01-06 |
Colora Corporation |
Pancreatic cancer targets and uses thereof
|
|
US7250398B2
(en)
|
2003-09-12 |
2007-07-31 |
Novozymes A/S |
Synthetic antimicrobial polypeptides
|
|
WO2008054561A2
(en)
*
|
2006-07-11 |
2008-05-08 |
University Of Medicine And Dentistry Of New Jersey |
Proteins, nucleic acids encoding the same and associated methods of use
|
|
EP2074142A4
(en)
|
2006-10-19 |
2010-10-27 |
Angiochem Inc |
COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
|
|
US8309034B2
(en)
*
|
2007-06-09 |
2012-11-13 |
Honeywell International Inc. |
Compositions, methods and devices for control and clean-up of hazardous spills
|
|
CA2709937C
(en)
*
|
2007-12-21 |
2016-03-22 |
Fibrotech Therapeutics Pty Ltd |
Halogenated analogues of anti-fibrotic agents
|
|
US11260133B2
(en)
|
2008-02-21 |
2022-03-01 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to peptides and proteins with C-terminal elements
|
|
AU2009291747B2
(en)
|
2008-09-10 |
2016-05-26 |
Genentech, Inc. |
Methods for inhibiting ocular angiogenesis
|
|
WO2013184482A1
(en)
|
2012-06-04 |
2013-12-12 |
Yale University |
Method of treating and preventing ocular angiogenesis
|
|
JP6692751B2
(ja)
*
|
2013-11-26 |
2020-05-13 |
イーアンドビー テクノロジーズ エルエルシー |
新規カベオリンモジュレーターを使用する自己免疫および／または炎症疾患の治療
|